Ocular Adverse Events Related To Mirvetuximab Soravtansine
Published 2026 - 44th Congress of the ESCRS
Reference: POCOR128 | Type: Case Report | DOI: 10.82333/65ra-bs44
Authors: Dr Tamara Shukair Harb* 1 , Dr Raul Sampedro 2 , Dr Hector Fernandez 2
1Ophthalmology,HM / CIOCC,Madrid,Spain, 2Ophthalmology,HM,Madrid,Spain
Purpose
Mirvetuximab Soravtansine (MIRV), novel potential anticancer drugs of antibody-drug conjugates (ADCs) , used for ovarian cancer. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye.
This review summarizes current evidence on the incidence, and clinical presentation of MIRV-related ocular adverse events . It also provides practical, evidence-based strategies for the monitoring, and management of these adverse events
Setting
Retrospective observational study . Data were extracted from the population , undergoing a clinical trials with Mirvetuximab soravtansine in a reference centre in Madrid between 2021–2024 (30 months)
Report of case
10 female patients with advanced ovarian cancer,Full ophthalmologic examination at each treatment cycle
8 patients with punctate keratitis , microcyst-like epithelial keratopathy grad II
3 patients with catarat progression .
The major Events are CTCAE grade II in both eyes . The median time to onset is 8-10 weeks. However, ocular toxicity may appear up to 4 months after treatment initiation, indicating a need for prolonged vigilance.
Treatment includes prophylactic topical therapies, supportive care measures, treatment delays or dose modifications
Conclusion/Take home message
Mirvetuximab Soravtansine (MIRV) realated with high risk of ocular toxicity,
New ocular toxicity signals not documented in product labeling were detected.Further research is essential to measure the real outcome of preventive strategies and it will be necessary to validate our results in the future.